<- Go Home
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Market Cap
$838.9M
Volume
476.0K
Cash and Equivalents
$48.3M
EBITDA
-$88.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$10.0M
Profit Margin
100.00%
52 Week High
$33.20
52 Week Low
$13.88
Dividend
N/A
Price / Book Value
2.75
Price / Earnings
-4.34
Price / Tangible Book Value
2.75
Enterprise Value
$636.5M
Enterprise Value / EBITDA
-7.37
Operating Income
-$90.0M
Return on Equity
44.95%
Return on Assets
-29.72
Cash and Short Term Investments
$211.5M
Debt
$9.1M
Equity
$304.6M
Revenue
$10.0M
Unlevered FCF
-$57.5M
Sector
Biotechnology
Category
N/A